Novavax, Inc. (NVAX) Company Profile & Statistics

Novavax, Inc.
NVAX
(Nasdaq - US)
Closed
8.48
+0.44 (+5.41%)
in:usd•As of: Nov 22, 2024 15:59 UTC -5
After Market:8.52+0.05 (+0.53%)
Open
8.08
High
8.62
Low
8.08

About Novavax, Inc.

CEO

John C. Jacobs

Headquarters

700 quince orchard road

gaithersburg, md 20878, united states

Auditor

Ernst & Young LLP

Employees

1,543

Share Holders

177

Website

www.novavax.com

Industry

biotechnology

Sector

health technology

Company Overview

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.?Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.?Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.?ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.

Novavax, Inc. Statistics

Valuation Measures

Market Capitalization ²	1.36B
Enterprise Value	1.01B
Enterprise Value/EBITDA (ttm)	-3.95
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	1.45
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	50.22%
Operating Margin (ttm)	-32.18%
Profit Margin (ttm)	-80.72%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	21.04%
Return on Assets (ttm)	-17.05%

Income Statement

Revenue (ttm)	885.19M
Revenue Per Share (ttm)	5.53
Gross Profit (ttm)	564.15M
EBITDA (ttm)³	-254.65M
Net Income Avi to Common (ttm)	-284.86M
Diluted EPS (ttm)	-2.26

Share Statistics

Beta (5Y Monthly)	2.10
52-Week Change	48.68%
S&P500 52-Week Change	30.93%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	160.19M
Dividend Yield	0.00%
Float ⁴	158.58M
% Held by Insiders	1.00%
% Held by Institutions	53.04%

Balance Sheet

Total Cash (mrq)	920.08M
Total Cash Per Share (mrq)	5.74
Total Debt (mrq)	233.31M
Total Debt/Equity (mrq)	-44.32%
Current Ratio (mrq)	0.93%
Quick Ratio (mrq)	0.93%
Book Value Per Share (mrq)	-3.29

Cash Flow

Operating Cash Flow Per Share (ytd)	0.54
Free Cash Flow (ytd)	74.78M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Novavax, Inc.

Trade With A Regulated Broker